{"entity":{"id":"nct05410145","kind":"trial","name":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed and Cetuximab in advanced solid tumours, run by D3 Bio (Wuxi) Co., Ltd, now recruiting.","summary":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation is a phase 1/2 interventional study registered as NCT05410145 by D3 Bio (Wuxi) Co., Ltd, with 442 participants planned, started 2022-08-03 and due to reach its primary completion in 2027-04. Interventions recorded: D3S-001, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed and Cetuximab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05410145","url":"https://clinicaltrials.gov/study/NCT05410145"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","cisplatin","carboplatin","pemetrexed","cetuximab"],"companies":["d3-bio-wuxi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05410145","phase":"1/2","setting":"A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","sponsor":"D3 Bio (Wuxi) Co., Ltd","participation":[{"nct":"NCT05410145","source":"https://clinicaltrials.gov/study/NCT05410145","fetchedAt":"2026-10-07T16:53:41.920Z","studySha256":"f70000fdc91fdf6383f59881af78c4eff8f05cb2f30ebd919be00a71352b8c73","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-15","leadSponsor":"D3 Bio (Wuxi) Co., Ltd","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":442,"enrolmentType":"ESTIMATED","siteCount":52,"recruitingSiteCount":51,"countries":["Australia","China","France","Germany","Hong Kong","Italy","Japan","South Korea","Spain","United States"]}],"started":"2022-08-03","startedType":"actual","enrolled":442,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05410145/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"d3-bio-wuxi","kind":"company","name":"D3 Bio (Wuxi)","route":"/companies/d3-bio-wuxi/"}]}}